Successful Delivery Of Interferon Without Injection;
June 21, 1999
AURORA, Ontario (BW HealthWire) - Helix BioPharma Corp.
(TSE:HBP.) announced Interferon-a has been successfully delivered
both dermally and transdermally, without the need for an injection,
utilizing the Biphasix(tm) delivery system in a study of seventeen
healthy human volunteers.
In a presentation to the Controlled Release Society in Boston,
Professor Marianna Foldvari, of the College of Pharmacy and
Nutrition at the University of Saskatchewan, presented the results
of a study of the delivery of therapeutic proteins through human
skin. The study showed a significant increase in anti-viral
activity in the skin and in the blood following the application of
an interferon-a-Biphasix(tm) patch when compared to a placebo.
"The results indicate significant levels of interferon-a in the
skin and blood," said Dr. Foldvari. "This new delivery technology
may also prove useful for the injectionless delivery of other
protein therapeutics such as insulin."
Interferons are prescription drugs presently given by injection
to treat human papilloma virus ("HPV"), as well as other diseases
including multiple sclerosis and hepatitis. Helix is developing an
interferon-a Biphasix(tm) cream to combat HPV, a sexually
transmitted disease linked to cervical cancer, that affects more
than 24 million North Americans.
The Toronto Stock Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this
News Release. Information contained in this news release includes
forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ
Helix BioPharma trades on the TSE under the symbol "HBP"
Contact: Helix BioPharma Corp., Aurora 905/841-2300 ext. 232,
905/841-2244; (FAX) E-Mail: firstname.lastname@example.org
Home | What is HCV | Transmission |
| Lab |
Links | Transplant |